Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
268 participants
INTERVENTIONAL
2003-06-30
2005-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
NCT02191397
Effect of Bupropion on Seizure Threshold in Depressed Patients
NCT03126682
Effects Of Antidepressants On Sexual Functioning In Adults
NCT00051272
Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder
NCT01541475
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT01163266
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extended-release bupropion (HCl)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Generally in good health.
* Subject must read and write at a level sufficient to provide written informed consent.
Exclusion Criteria
* Subject has a primary diagnosis or received treatment for panic disorder, obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), acute stress disorder, Bipolar I or II disorder, schizophrenia, or other psychotic disorder.
* Currently using illicit drugs or other psychotropic drugs.
* Patient poses a current suicidal risk or has attempted suicide in the past 6 months.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials, MD
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Sherman Oaks, California, United States
GSK Investigational Site
Temecula, California, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Cromwell, Connecticut, United States
GSK Investigational Site
Hamden, Connecticut, United States
GSK Investigational Site
Middletown, Connecticut, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Marietta, Georgia, United States
GSK Investigational Site
Oak Brook, Illinois, United States
GSK Investigational Site
Cedar Rapids, Iowa, United States
GSK Investigational Site
Rockville, Maryland, United States
GSK Investigational Site
Farmington Hills, Michigan, United States
GSK Investigational Site
Ridgeland, Mississippi, United States
GSK Investigational Site
Moorestown, New Jersey, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Beachwood, Ohio, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Lincoln, Rhode Island, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Lake Jackson, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rush J, VanMeter SA, Wightman D, Hampton KD, Krishen A, Modell JG. Wellbutrin XL for the treatment of adults with major depressive disorder. American Psychiatric Association 158th Annual Meeting, Atlanta, GA, 21-26 May, 2005, Abstract No. 787.
Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006 Jun;67(6):865-73. doi: 10.4088/jcp.v67n0602.
Rush J, VanMeter SA, Wightman DS, Hampton KD, Krishen A, Modell JG. Bupropion XL for the treatment of adults with major depressive disorder. 45th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, 6-9June, 2005.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AK130931
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.